Sponsorship
This conference is co-sponsored by:

and Imedex®
Continuing Education
Physicians
The University of Arkansas for Medical Sciences (UAMS) College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Arkansas for Medical Sciences (UAMS) College of Medicine designates this educational activity for a maximum of 12.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Clinical Laboratory Specialists
Imedex, LLC has applied for approval as a provider of continuing education programs in the clinical laboratory sciences through the ASCLS P.A.C.E.® program. This is an advanced level instructional program. This activity is expected to award a maximum of 12 contact hours of advanced continuing education in the clinical laboratory sciences.
Pharmacy
Imedex, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This course (Universal Activity Number 0408-0000-09-003-L01-P) has been approved for a maximum of 12.25 contact hours (1.225 CEUs). No partial credit will be awarded. Participants must complete an activity evaluation form and credit request form at the conclusion of the activity. Statements of credit will be issued via email or USPS within eight weeks of the conclusion of the activity. There is a fee to participate in this activity.
Who Should Attend
This educational activity is specifically designed for infectious disease specialists, microbiologists, epidemiologists, laboratory technologists, and other healthcare professionals with special education and training in microbiology, mycology, or infectious diseases who are interested in identifying, diagnosing, and managing invasive fungal infections.
Objectives
Upon completion of this activity, participants should be able to:
- Restate current trends in the epidemiology of invasive fungal infections, based on recent surveillance reports
- Discuss recent technological advances in the detection and diagnosis of invasive fungal infections
- Review key considerations in managing pediatric fungal infections
- Describe optimal antifungal therapy for hematogenous candidiasis, in accordance with the 2009 IDSA clinical practice guidelines
- Compare and contrast conventional and novel treatments for invasive aspergillosis, in accordance with the 2009 IDSA clinical practice guidelines
- Summarize the latest diagnostic and treatment techniques for managing zygomycoses
- Integrate conventional and emerging antifungal treatment options into clinical practice, delivering a higher level of patient care
Learning Objectives for Pharmacists
Upon completion of this activity, participants should be able to:
- Restate current trends in the epidemiology of invasive fungal infections, based on recent surveillance reports
- Discuss recent technological advances in the detection and diagnosis of invasive fungal infections
- Review key considerations in managing pediatric fungal infections
- Describe optimal antifungal therapy for hematogenous candidiasis, in accordance with the 2009 IDSA clinical practice guidelines
- Compare and contrast conventional and novel treatments for invasive aspergillosis, in accordance with the 2009 IDSA clinical practice guidelines
- Summarize the latest diagnostic and treatment techniques for managing zygomycoses
- Understand and discuss the benefits and limitations of conventional and emerging antifungal treatment options
Disclosure Statement
It is the policy of the University of Arkansas for Medical Sciences (UAMS) College of Medicine to ensure balance, independence, objectivity, and scientific rigor in all sponsored or jointly sponsored educational activities. All individuals who are in a position to control the content of the educational activity (course/activity directors, planning committee members, staff, teachers, or authors of CME) must disclose all relevant financial relationships they have with any commercial interest(s) as well as the nature of the relationship. Financial relationships of the individual’s spouse or partner must also be disclosed, if the nature of the relationship could influence the objectivity of the individual in a position to control the content of the CME. The ACCME describes relevant financial relationships as those in any amount occurring within the past 12 months that create a conflict of interest. Individuals who refuse to disclose will be disqualified from participation in the development, management, presentation, or evaluation of the CME activity.
Elias J. Anaissie, MD
University of Arkansas for Medical Sciences
Little Rock, Arkansas
L. R. Baden, MD
Brighman and Women's Hospital
Boston Massachusetts
John E. Bennett, MD
National Institutes of Health
Bethesda, Maryland
Eric J. Bow, MD
CancerCare Manitoba Health Sciences Centre
Winnipeg, Manitoba, Canada
Ben E. de Pauw, MD, PhD
Radboud University, Nijmegen Medical Center
Nijemgen, Netherlands
Annette W. Fothergill, MA, MBA
University of Texas Health Science Center at San Antonio
San Antonio, Texas
Paul O. Gubbins, PharmD
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Tobias M. Hohl, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, New York
Kieren A. Marr, MD
Johns Hopkins University
Baltimore, Maryland
Marcio Nucci, MD
Federal University of Rio de Janeiro
Rio de Janeiro, Brazil
Luis Ostrosky-Zeichner, MD, FACP, FIDSA
University of Texas Health Science Center at Houston
Houston, Texas
Thomas F. Patterson, MD, FACP, FIDSA
University of Texas Health Science Center at San Antonio
San Antonio, Texas
John R. Perfect, MD
Duke University Medical Center
Durham, North Carolina
Michael A. Pfaller, MD
University of Iowa
Iowa City, Iowa
Michael G. Rinaldi, PhD
University of Texas Health Science Center at San Antonio
San Antonio, Texas
Coleman Rotstein, MD, FRCPC, FACP
University of Toronto
Toronto, Ontario, Canada
Brahm H. Segal, MD
Roswell Park Cancer Institute
Buffalo, New York
William J. Steinbach, MD
Duke University
Durham, North Carolina
Deanna A. Sutton, PhD
University of Texas Health Science Center at San Antonio
San Antonio, Texas
Thomas J. Walsh, MD
National Cancer Institute
Bethesda, Maryland
John R. Wingard, MD
University of Florida College of Medicine
Gainesville, Florida
Wednesday, March 3, 2010
2:00 pm
Mycology Workshop
Annette W. Fothergill, MA, MBA and Deanna A. Sutton, PhD
4:00 pm
Adjourn
Thursday, March 4, 2010
7:45 am
Welcome
Elias J. Anaissie, MD and Michael G. Rinaldi, PhD
Session I: Candidiasis
This session is brought to you in collaboration with The Association of Medical Microbiology and Infectious Disease Canada (AMMI)
Moderators: Coleman Rotstein, MD, FRCPC, FACP and Thomas J. Walsh, MD
8:00 am
Audience Response System Case #1
A patient with hematogenous candidiasis after liver transplantation
Coleman Rotstein, MD, FRCPC, FACP
8:10 am
Risk factors in non-neutropenic hosts
Coleman Rotstein, MD, FRCPC, FACP
8:30 am
Diagnosis of candidiasis: What works and what doesn’t?
Michael A. Pfaller, MD
8:50 am
Panel Discussion of audience response system Case #1 with audience participation
9:20 am
Coffee break
9:40 am
Audience Response System Case #2
Septic shock caused by Candida albicans in a patient with acute leukemia
Eric J. Bow, MD
9:50 am
The alimentary tract and candidiasis in neutropenic patients
Eric J. Bow, MD
10:10 am
What constitutes optimal antifungal therapy for hematogenous candidiasis – Any role for combination therapy?
Luis Ostrosky-Zeichner, MD, FACP, FIDSA
10:30 am
Panel discussion of Case #2 with audience participation
11:00 am
Controversies and unresolved issues in the 2009 IDSA candidiasis guidelines – With comment on efficacy of different echinocandins
Marcio Nucci, MD
11:20 am
Lunch Symposium -
Clinical Implications of Recent Mycological Research in Cryptococcosis
Presented by the Medical Mycological Society of the Americas
Session II: MMSA Keynote Lecture
1:00 pm
MMSA Keynote Lecture
Speaker invited
1:30 pm
Special Lecture
This lecture is brought to you in collaboration with the International Pediatric Fungal Network
Key considerations in managing pediatric fungal infections
William J. Steinbach, MD
Session III: Zygomycosis
This session is brought to you in collaboration with The Immunocompromised Host Society and INFOCUS Latin America
Moderator: Marcio Nucci, MD
2:00 pm
Audience Response System Case #3
A patient with hematologic cancer and invasive sinusitis caused by Rhizopus spp.
Thomas J. Walsh, MD
2:10 pm
Zygomycosis: An update on pathogenesis and diagnosis
Thomas J. Walsh, MD
2:30 pm
Coffee Break
2:50 pm
How I manage zygomycosis
Luis Ostrosky-Zeichner, MD, FACP, FIDSA
3:10 pm
Panel discussion of Case #3 with audience participation
3:30 pm
Special Lecture:
The modern work-up and treatment of Pneumocystis jiroveci pneumonia
L. R. Baden, MD
4:00 pm
Poster viewing
Friday, March 5, 2010
8:00 am
Welcome
Elias J. Anaissie, MD
Michael G. Rinaldi, PhD
Session IV: Aspergillosis
This session is brought to you in collaboration with The Immunocompromised Host Society and Advances Against Aspergillosis
Moderator: John R. Wingard, MD
8:10 am
Audience Response System Case #4
An allogeneic stem cell transplant recipient develops invasive pulmonary aspergillosis
John R. Wingard, MD
8:20 am
Viruses and fungi: Birds of a feather?
Kieren A. Marr, MD
8:40 am
Conventional and novel risk factors for invasive aspergillosis
Brahm H. Segal, MD
9:00 am
How I treat aspergillosis in patients with acute leukemia: Any role for combination antifungal therapy?
Eric J. Bow, MD
9:20 am
Prophylaxis or diagnosis-based preemptive therapy: Will this really decrease the use of empiric antifungal therapy?
Ben E. de Pauw, MD, PhD
9:40 am
Panel discussion of Case #4 with audience participation
10:10 am
Coffee Break and Poster Viewing
10:30 am
How the respiratory immune system initiates innate and adaptive responses to aspergillus spores
Tobias M. Hohl, MD, PhD
10:50 am
Aspergillosis: Unanswered questions in the new IDSA guidelines
John E. Bennett, MD
11:10 am
Therapeutic drug monitoring: When and how?
Paul O. Gubbins, PharmD
11:30 am
Panel discussion
12:00 pm
Presentation of Thomas J. Walsh Mycology Award
Elias J. Anaissie, MD
Michael G. Rinaldi, PhD
12:10 pm
Lunch
Session V: Looking into the future of clinical mycology
Moderator: John R. Perfect, MD
1:10 pm
Special Lecture
Practice changing papers in mycology: The top five in the past five years
Speaker Invited
1:40 pm
Antifungal therapy: Novel targets
Thomas J. Walsh, MD
2:00 pm
The antifungal pipeline: An update on new agents from the 2009 ICAAC and IDSA meetings and beyond
Thomas F. Patterson, MD,
FACP, FIDSA
2:20 pm
Adjourn
Call for Abstracts
Participants interested in presenting data should should first register or log in, then submit abstracts online by Tuesday, January 19, 2010. Abstracts are subject to acceptance by the Scientific Committee.
Acceptance notifications and guidelines for poster presentation will be sent on Tuesday,
February 9, 2010. Authors of accepted abstracts who have not registered will have until February 17, 2010 to do so at the rate of $299.00. After this date, abstracts without registered presenters will be disregarded.
Abstract Guidelines
- Follow the online instructions
- Abstracts must be written in English
- Accepted format: Word document format, 9 point Arial font, 500 word count limit
- Use a concise title
- List affiliations of author(s) as briefly as possible, with city, state, and country
- Place an asterisk (*) before the name
of the presenting author
- Use standard and well-accepted abbreviations
- When using references, use standard and well-accepted formats
- Abstract content should be
single-spaced, typed in lower case and contain:
–Purpose of the study
–Summarized description of
the project
–Results and conclusions
Abstract Awards
The Thomas J. Walsh Mycology Award
The Thomas J. Walsh Mycology Award was established to encourage and recognize scientific research excellence. The award will be presented to the best overall abstract presented at Focus on Fungal Infections 20. The recipient will be awarded a research grant of $5,000 for utilization in their professional work. The first author must meet the following requirements:
- Candidate must show original research of major importance in the field of medical/clinical mycology conducted by themselves and co-investigators (if any)
- The selected abstract should not have been presented previous to Focus on Fungal Infections 20
- Candidate must show relevance of
the work to a current problem in patients involving fungal infections (in the broadest sense) in contemporary medicine
- Candidate must submit a well-written, concise, and accurate abstract
- Candidate must be registered
for the meeting and agree to be present during the scheduled presentation times
Submission Deadline:
Tuesday, January 19, 2010
Registration Fees
Discounted (Payment received by January 28, 2010)
Physician - $299
*Pharmacist -
$175
Regular (Payment received by February 24, 2010)
Physician - $399
*Pharmacist - $225
Full/Onsite (Payment received after February 24, 2010)
Physician - $499
*Pharmacist -
$250
Group discount (Physicians only (cannot be combined with any other discounts)*
-$50
Nurses/Residents/Students*
$99
* Proof of eligibility must accompany registration
To Register: You may register online by February 24, 2010, or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting.
To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.
The on-site Registration and Information Desk will be staffed:
March 3, 2010, 12:00 pm – 4:00 pm
March 4, 2010, 7:00 am – 4:00 pm
March 5, 2010, 7:00 am – 3:00 pm
Group Discounts: Each one of multiple registrants from the same institute or practice will receive a $50 discount off the published registration fees, provided all registration forms and payments are received together. Only one discount will apply per physician. Discounts are not available for pharmacist rate.
Payment: To pre-register, registration and payment must be received no later than February 24, 2010. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.
Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda.
Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than February 24, 2010. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after February 24, 2010.
Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this program should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.
Hotel Accommodations
Hilton New Orleans Riverside
2 Poydras Street
New Orleans, Louisiana, 70140, USA
Tel.: +1 504 561 0500
Fax: +1 504 568 1721
www1.hilton.com
Visiting the Hilton New Orleans Riverside will not only bring back fond memories, but can open up new areas to explore in New Orleans, Louisiana. The Hilton New Orleans Riverside, a full service luxury complex, is actually a "city within itself" with a redesigned front desk and guest service area to increase efficiency and enhance service; featuring “BoardEZ” computers to print boarding passes which are adjacent to our full service business center.
In the ''center of it all.'' The Hilton New Orleans Riverside, where distance is measured in feet, not cab fare, is in a prime downtown location on the banks of the Mississippi. The Riverwalk is at the hotel's doorstep.
For the convenience of attendees, a limited number of rooms have been reserved until February 9, 2010 at a discounted rate of $159.00 single/double occupancy, plus tax, currently at 13% and a $3.00 occupancy tax per room per night. This rate is not guaranteed outside the conference dates or after February 9, 2010.
To reserve your room please contact the Hilton New Orleans Riverside reservations department at +1 504 561 0500 or by clicking here. To receive the group rate, callers must identify themselves as being with the Focus on Fungal Infections 20 group. Reservation requests received after February 9, 2010 may not be guaranteed the group rate.
Dear Colleagues,
It is our great pleasure to invite you to the 20th meeting of Focus on Fungal Infections, to be held from March 3-5, 2010 in New Orleans, Louisiana. This meeting will be an excellent opportunity to share and increase your knowledge of ongoing research on fungal infections and how to optimize patient care.
The last few years have seen progressive changes in our approach to fungal disease. Greater understanding of recent scientific advances has led to incorporating this data into strategies for patient management. Our meeting this year features special lectures prepared in collaboration with professional organizations, a new keynote lecture, and a review of practice-changing papers, providing many opportunities for the dissemination, discussion and debate of the new medical and scientific information. As an integral part of the meeting, researchers working in the field have the opportunity to interact with colleagues and share their endeavors with the healthcare community. We invite you to participate in this year’s meeting by submitting an abstract of your work to be considered for presentation.
A great deal of thought went into formulating not only a stimulating scientific program, but also the preparation of a most enjoyable celebration of 20 successful years, which will give participants the opportunity to experience the collegial atmosphere that has made Focus on Fungal Infections a “must attend” meeting. New Orleans, with its many attractions and the focus of so much attention by medical mycologists following Hurricane Katrina, will provide the ideal forum for scientific exchange.
We very much look forward to your participation in 2010!
Sincerely,
Elias J. Anaissie, MD and Michael G. Rinaldi, PhD
Chairs, Focus on Fungal Infections 20
ORGANIZER
Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

Sponsorship
This conference is sponsored by:

Endorsed by







Conference Location
Hilton New Orleans Riverside
2 Poydras Street
New Orleans, Louisiana, 70140, USA
Tel.: +1 504 561 0500
Fax: +1 504 568 1721
www1.hilton.com
Important Dates:
Abstract Notifications Mailed:
February 9, 2010
Abstract Presenter Registration Deadline:
February
24, 2010
Regular Registration Deadline:
February 24, 2010
Presentation Dates:
March 3-5, 2010
Comments from Past Participants:
"Excellent review of therapeutic studies – Each presenter provided meaningful information"
"Use of response innovations for audience questions was excellent"
"Outstanding fact-filled conference"
"Controversies were great – Extremely useful and critical discussion"
"Excellent conference!"
Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.
In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.
©2009 Imedex®, LLC. All rights reserved.
Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.
The following company has provided an educational grant in support of this conference:

Several options are available to companies interested in supporting this conference. For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.
The following companies will be exhibiting at this conference:






Opportunities are available to companies interested in exhibiting at this conference. For more information, please contact Cori Gunter at +1(678) 242 0712, or by email at c.gunter@imedex.com.